 |
인쇄하기
취소
|
Ildong's Samion likely to get more sales
Ildong Pharm's Samion (nicergolin), cererovascular medine, is expected to increase as leading ginkgo biloba preparations Ginexin and Tanamin will be non-eligible for health insurance from this May.
Ildong garnered 16.5 billion won in Samion sales last year.
Most of nicergolin drug makers discontinued the production due to sluggish sales.
Experts say that Samion will be highlighted as...
Ildong garnered 16.5 billion won in Samion sales last year.
Most of nicergolin drug makers discontinued the production due to sluggish sales.
Experts say that Samion will be highlighted as...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.